The 1β-Hydroxy-Deoxycholic Acid to Deoxycholic Acid Urinary Metabolic Ratio: Toward a Phenotyping of CYP3A Using an Endogenous Marker?

Détails

Ressource 1Télécharger: jpm-11-00150.pdf (4769.38 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_8186FF4285F1
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
The 1β-Hydroxy-Deoxycholic Acid to Deoxycholic Acid Urinary Metabolic Ratio: Toward a Phenotyping of CYP3A Using an Endogenous Marker?
Périodique
Journal of personalized medicine
Auteur⸱e⸱s
Magliocco G., Desmeules J., Bosilkovska M., Thomas A., Daali Y.
ISSN
2075-4426 (Print)
ISSN-L
2075-4426
Statut éditorial
Publié
Date de publication
20/02/2021
Peer-reviewed
Oui
Volume
11
Numéro
2
Pages
150
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
In this study, we assessed the potential use of the 1β-hydroxy-deoxycholic acid (1β-OH-DCA) to deoxycholic acid (DCA) urinary metabolic ratio (UMR) as a CYP3A metric in ten male healthy volunteers. Midazolam (MDZ) 1 mg was administered orally at three sessions: alone (control session), after pre-treatment with fluvoxamine 50 mg (12 h and 2 h prior to MDZ administration), and voriconazole 400 mg (2 h before MDZ administration) (inhibition session), and after a 7-day pre-treatment with the inducer rifampicin 600 mg (induction session). The 1β-OH-DCA/DCA UMR was measured at each session, and correlations with MDZ metrics were established. At baseline, the 1β-OH-DCA/DCA UMR correlated significantly with oral MDZ clearance (r = 0.652, p = 0.041) and C <sub>max</sub> (r = -0.652, p = 0.041). In addition, the modulation of CYP3A was reflected in the 1β-OH-DCA/DCA UMR after the intake of rifampicin (induction ratio = 11.4, p < 0.01). During the inhibition session, a non-significant 22% decrease in 1β-OH-DCA/DCA was observed (p = 0.275). This result could be explained by the short duration of CYP3A inhibitors intake fixed in our clinical trial. Additional studies, particularly involving CYP3A inhibition for a longer period and larger sample sizes, are needed to confirm the 1β-OH-DCA/DCA metric as a suitable CYP3A biomarker.
Mots-clé
CYP450, phenotyping, CYP3A, bile acid, biomarker
Pubmed
Web of science
Open Access
Oui
Création de la notice
22/02/2021 12:55
Dernière modification de la notice
21/11/2022 8:23
Données d'usage